Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 2, 2012, Pages 118-126

  Teoh, Gerrard ^a,b   Chen, Yuming ^c   Kim, Kihyun ^d   Srivastava, Alok ^e   Pai, Vasant R ^f   Yoon, Sung Soo ^g   Suh, Cheolwon ^h   Kim, Yeo Kyeoung ⁱ  

^a GLENEAGLES HOSPITAL   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

^d Samsung Medical Center   (South Korea)

^e CHRISTIAN MEDICAL COLLEGE   (India)

^f TATA MEMORIAL HOSPITAL   (India)

^g Seoul National University Hospital   (South Korea)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ Chonnam National University   (South Korea)

Author keywords

Antimyeloma effect; Asian patients; Dexamethasone; Thalidomide; Zoledronic acid

Indexed keywords

DEXAMETHASONE; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; ASIAN; BEDTIME DOSAGE; BONE PAIN; CONTROLLED STUDY; DRUG FATALITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FRACTURE; HEART ARRHYTHMIA; HEMATOMA; HUMAN; HYPOPROTEINEMIA; INFECTION; JAW OSTEONECROSIS; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OSTEOCLAST; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SEPSIS; UREMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84858984485     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.11.002     Document Type: Article

References (62)

1. Bergsagel DE, Sprague CC, Austin C, et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep 1962; 21:87-99.
2. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208:680-5.
3. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353-6. (Pubitemid 14149087)
4. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-23. (Pubitemid 35266292)
5. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-9.
6. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26:2171-7.
7. Uaprasert N, Voorhees PM, Mackman N, et al. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer 2010; 46:1790-9.
8. Guo H, Zhou X, Jiang Y, et al. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience. Am J Hematol 2010; 85:499-501.
9. Kim YK, Sohn SK, Lee JH, et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 2010; 89:475-82.
10. Lü S, Wang J, Xu X, et al. Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol 2009; 89:34-8.
11. Chen SL, Jiang B, Qiu LG, et al. Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China. Anat Rec (Hoboken) 2010; 293:1679-84.
12. Murakami H, Shimizu K, Sawamura M, et al. Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol 2009; 89:636-41.
13. Mitsiades CS, McMillin DW, Klippel S, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007; 21:1007-34. (Pubitemid 350051349)
14. Fowler JA, Edwards CM, Croucher PI. Tumor-host cell interactions in the bone disease of myeloma. Bone 2011; 48:121-8.
15. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376:1989-99.
16. Teoh G, Hwang W, Koh LP, et al. Low dose dexamethasone and thalidomide with higher frequency zoledronic acid (dtZ) for multiple myeloma. Blood 2004; 104(11); abstr 4915.
17. Teoh G, Hwang W, Koh LP, et al. Low dose dexamethasone and thalidomide with higher frequency zoledronic acid (dtZ) for relapsed/refractory multiple myeloma. Haematologica 2005; 90(S1):141-2; abstr PO.710.
18. Boccadoro M, Palumbo A, Bringhen S, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87:846-50. (Pubitemid 34851555)
19. Ghobrial IM, Dispenzieri A, Bundy KL, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003; 32:587-92. (Pubitemid 37185094)
20. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004; 103:20-32. (Pubitemid 38029914)
21. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20:117-20.
22. Treister N, Sheehy N, Bae EH, et al. Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 2009; 15:88-92.
23. Montefusco V, Gay F, Spina F, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008; 49:2156-62.
24. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010; 136:1117-24.
25. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27:5356-62.
26. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23. (Pubitemid 28435189)
27. Marks SC Jr, Walker DG. The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors. Am J Anat 1981; 161:1-10. (Pubitemid 11104658)
28. Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 2010; 89:201-6.
29. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001; 20: 859-66. (Pubitemid 32249085)
30. Wilson EB. On confidence intervals. Proc Natl Acad Sci U S A 1942; 28:88-93.
31. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-20.
32. Weide R, Koppler H, Antras L, et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther 2010; 6:31-5.
33. Tosi P, Terragna C, Testoni N, et al. Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. Eur J Haematol 2008; 80:31-6. (Pubitemid 350265226)
34. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906-17.
35. Jagannath S, Durie BG, Wolf JL, et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009; 146:619-26.
36. Rosiñol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multipl myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25:4452-8. (Pubitemid 350013852)
37. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23:1337-41.
38. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29-37.
39. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82:1179-84. (Pubitemid 47502875)
40. Palumbo A, Falco P, Corradinients with newly diagnosed multiple myeloma. Blood, 2010; 116:679-86.dependent on osteoclast activity. Br J Haematol, 2002; 116:278-90
41. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116:679-86.
42. Terpos E, Berenson J, Cook RJ, et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010; 24:1043-9.
43. Allegra A, Alonci A, Penna G, et al. Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol 2010; 124:79-85.
44. Hokugo A, Christensen R, Chung EM, et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 2010; 25:1337-49.
45. Lindqvist PG, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. J Thromb Haemost 2009; 7:605-10.
46. Ng AC, Kumar SK, Rajkumar SV, et al. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 2009; 84:397-400.
47. Brown HK, Holen I. Anti-tumour effects of bisphosphonates - what have we learned from in vivo models? Curr Cancer Drug Targets 2009; 9:807-23.
48. Lawson MA, Ashcroft J, Croucher PI. Bisphosphonate therapy in the treatment of multiple myeloma. Curr Pharm Des 2010; 16:3028-36.
49. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010; 126:239-46.
50. Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116:278-90. (Pubitemid 34156975)
51. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28:2612-24.
52. Nooka A, Kaufman J, Lonial S. The importance of complete response in outcomes in myeloma. Cancer J 2009; 15:465-72
53. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009; 114:3139-46.
54. Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008; 113:355-9.
55. Andersen TL, Sondergaard TE, Skorzynska KE, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009; 174:239-47.
56. Roodman GD. Osteoblast function in myeloma. Bone 2011; 48:135-40.
57. Levy J, Roodman GD. The role of bisphosphonates in multiple myeloma. Curr Hematol Malig Rep 2009; 4:108-12.
58. Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 2010; 51:213-20.
59. Roodman GD. Bone building with bortezomib. J Clin Invest 2008; 118:462-4. (Pubitemid 351206534)
60. Yao Z, Li P, Zhang Q, et al. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 2006; 281:11846-55. (Pubitemid 43855445)
61. Komano Y, Nanki T, Hayashida K, et al. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther 2006; 8:R152.
62. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15:1467-76. (Pubitemid 30484516)